The coronavirus disease 2019 (COVID-19) has induced a substantial burden to global health in terms of its morbidity and mortality. The Severe Acute Respiratory Syndrome (SARS) in 2003, the Mediterranean East Respiratory Syndrome (MERS) in 2012 and the present COVID-19 pandemic in 2019 are caused by the same *Betacoronavirus* genus---although SARS and MERS are mainly associated with nosocomial spread whilst COVID-19 is transmitted in the community \[[@CR1]\]. There is a recent update on the emergence of SARS-like coronavirus in China \[[@CR2]\]. Both SARS-CoV and MERS-CoV were believed to originate in bats and were directed transmitted to humans from market civets and dromedary camels, respectively \[[@CR3]\]. It was also highlighted that SARS-CoV-2 could display an identity of up to 88% at the nucleotide sequence level with bat SARS-like CoV genomes \[[@CR4]\]. There are a number of significant differences among the three types of SARS-like viruses. When compared with COVID-19, SARS and MERS had much lower transmissibility in terms of their reproductive number, yet their fatality rates are significantly higher. There are, nevertheless, similarities among the three pandemics in terms of their control measures at the country level, including risk communication, isolation strategies, and quarantine policies. There has been much discussion regarding whether healthcare policy-makers could learn from previous infectious disease outbreaks such as SARS and MERS---from which the experience might be beneficial to combat the current COVID-19 pandemic. We aimed to evaluate the potential effectiveness of exposure to SARS and/or MERS on incidence of COVID-19 per 100,000 population within 30 days from the first confirmed case reported.

We have previously examined the susceptibility of a country to hazardous incidents and lack of inadequate resources in alleviation of the COVID-19 pandemic based on the INFORM score devised by the European commission \[[@CR5]\]. It was found that countries with lower public interest in face mask; a higher COVID-19 vulnerability and lack of coping capacity; as well as those less equipped with certain non-pharmaceutical features \[[@CR6]\] were associated with a higher COVID-19 incidence and mortality, after controlling for potential confounding factors. In this study, we retrieved the same incidence outcome as the previous study did \[[@CR5]\] from the 2019 Novel COVID-19 data repository by the Johns Hopkins Centre for Systems Science and Engineering (CSSE). A 30-day period was used based on references from published reports. Data on the countries affected by SARS and MERS were extracted from the WHO. We tested the association between the 30-day incidence of COVID-19 and the country-level exposure to SARS and/or MERS, whilst controlling for potential confounders including the INFORM COVID-19 Risk Index, Testing Policies, Democracy Index, Scientific Citation Index, Gross Domestic Product (GDP), Human Development Index (HDI) and the population density. The INFORM COVID-19 Risk Index is a composite score to identify countries at risk from health and humanitarian impacts of COVID-19 that could overwhelm current national response capacity and to support prioritization of preparedness and early response actions for the primary impacts of the pandemic. The COVID-19 testing policies were collected for each country. The Democracy Index in 2019, which evaluated electoral process and pluralism; civil liberties; the functioning of government; political participation; and political culture, was used in the analysis. Scientific Citation Index is defined as the total citations updated to 2019 for each country using data from Scopus. We constructed a multivariable linear regression model with the incidence measure as the outcome variable. We considered *p* values \< 0.05 as statistically significant. From a literature search of the WHO database, there were 29, 27 and 213 countries or regions affected by SARS, MERS and COVID-19 at the time of this study, respectively. Figure [1](#Fig1){ref-type="fig"} illustrates the spatial distribution of countries affected by these three pandemics by the world maps. Table [1](#Tab1){ref-type="table"} shows that countries with previous exposure to SARS and/or MERS epidemics were significantly more likely to have lower incidence of COVID-19 (*β* coefficient − 225.6, 95% C.I. − 415.8, − 35.4, *p* = 0.021), after control of potential confounders. However, countries being classified as having "full democracy" using Democracy Index had higher incidence of COVID-19 (reference: authoritarian regime; *β* coefficient 425.0, 95% C.I. 98.0, 752.0, *p* = 0.011). There was no variable interaction or multicollinearity detected. The leave-one-out cross-validation did not identify any model error driven by a single country for both previous MARS/SARS exposure (Root Mean Squared Errors (MSE): 430.8 \< 469.4) and Democracy Index (Root MSE: 422.9 \< 555.0).Fig. 1Spatial distribution of countries affected by Severe Acute Respiratory Syndrome (SARS), Mediterranean East Respiratory Syndrome (MERS), and 2019 coronavirus disease (COVID-19)Table 1The association between exposure to SARS and/or MERS and the incidence of COVID-19 per 100,000 population within 30 days from the report of the first confirmed caseEpidemics\*Number of countries affectedSARS29MERS27COVID-19 (as of 05 June, 2020)216Potential factors associated with incidence*β* coefficients (95% C.I.)*p* valueNever exposure to SARS and/or MERSReferenceExposure to SARS and/or MERS− 225.6 (− 415.8,− 35.4)0.021Inform COVID-19 risk index66.9 (− 56.6, 190.3)0.285Testing policies114.8 (− 42.4, 272.0)0.150Democracy index Authoritarian regimeReference Hybrid regime− 24.0 (− 314.8, 266.9)0.870 Flawed democracy− 43.2 (− 295.8, 209.4)0.735 Full democracy425.0 (98.0, 752.0)0.011Scientific citation index0.04 (− 5.14, 5.23)0.987GDP per capita− 28.5 (− 103.9, 46.9)0.454HDI1236.8 (− 66.1, 2539.7)0.063Population density− 20.0 (− 122.0, 82.0)0.698\*References from: WHO. Summary of probably SARS cases with onset of illness from 1 November 2002 to 31 July 2003. Available at: <https://www.who.int/csr/sars/country/table2004_04_21/en/>. Accessed on 05 June, 2020; WHO. Middle East respiratory syndrome coronavirus (MERS-CoV). Available at: <https://www.who.int/emergencies/mers-cov/en/>. Accessed on 05 June, 2020; Updated figures from the WHO. Available at: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019>, Accessed on 05 June, 2020

This finding supports that previous exposure to global epidemics and democracy index are associated with the position to respond to COVID-19. Previous pandemic experience might have improved the capabilities to identify and diagnose novel pathogens at a country level, and mitigation strategies might have been implemented more rapidly and effectively to contain the virus. These might include a rapid sharing of the SARS-CoV-2 genetic information; rapid development of diagnostic tests and their implementation; as well as containment and quarantine policies that have mediated a global approach to minimise the spread of COVID-19 by co-coordination of international resources \[[@CR1]\]. These findings also encourage national policies to be consolidated by a comprehensive review of effective strategies in this COVID-19 pandemic to enhance population resilience, global health security capacities, surveillance, stringency of containment strategies, isolation measures, and various policies at the individual, community and national levels. A major limitation of the study includes the possible presence of confounders, including number of tests and different short-term strategies, since there is a lack of validated measurement and available data on these factors in all countries. Another limitation is that the cause-and-effect relationships between the exposure to SARS or MERS and the pandemic control of COVID-19 could not be established as a cross-sectional design was adopted in the current study. Future studies that adopt a prospective approach are therefore required to examine the impact of various pandemic control strategies at individual, community, and policy levels on COVID-19 mitigation.
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